News on Alzheimer's disease (AD) frontline:
The fake data on Nature misled the research and product development for more than 16 years since 2006!
The devastating consequence and the detailed discussion please refer to Science editor Derek Lowe's blog:
https://www.science.org/content/blog-post/faked-beta-amyloid-data-what-does-it-mean
Another victim: Roche announced the failure of their monoclone antibody drug for Alzheimer's recently. (https://www.reuters.com/business/healthcare-pharmaceuticals/roche-suffers-setback-with-alzheimers-treatment-2022-06-16/)
Not by luck, our technology and product BrainGlucose are based on our own theory of Free Energy, Functional Group Interaction and Memory Protein Stability, which was presented in the Alzheimer's Association International Conference (AAIC) 2013 in Boston by Dr. Xia. That is why our BrainGlucose has been saving Alzheimer's patients since January 2017!
Thank you so much for all of our returned customers for years!
On 1-21-2021, Stanford Medicine researchers published study in Nature. The study further proved the published results of Yale Medical 10-19-2017 and Temple Univ. Med School study on 1-31-2017, that deprivation of glucose is the cause of Alzheimer's disease (AD). Even though the study did not dig deeper why glucose converting into glycogen, it explains our BrainGlucose role in saving mid-stage AD by pushing the equilibrium towards more glucose available for energy utilization after midnight, when higher energy demanding and memory related REM dream cycles occur, and it clearly prevents the typical clinical symptoms of hallucinations, nightmares, and night sweats of nocturnal hypoglycemia in brain.
Company news: We are pleased to announce that ACL is granted new patents by USPTO and Canadian patent authority. They broaden our existing patent scope and place our AddMem device in a unique strategic position.
Currently, we own total 4 patents.
*****************************************************************************************
ACL is a company with patent granted technologies in brain science. Our products can be easily adopted by home care settings. They reduce the burden of families, PCPs and the other caregivers for patients, and the cost for insurance industry and the whole society.
ACL is a licensed manufacturer by Pennsylvania State government for our medical food products.
After achieving miraculous therapy for early and mid stage Alzheimer’s patients by our flagship product BrainGlucose, Able Cerebral is migrating gradually to a pharmaceutical and medical device company in order to improve health accessibility:
1. Advancing our BrainGlucose to phase III clinical study so it can be available to more patients as a new drug product. We plan to complete this goal by 2025.
2. Welcome Investments and Collaborations for continuing our efforts to develop AddMem, a class 1 medical device with groundbreaking technologies for individualized memory RECOVERY. It may benefit moderate to severe stage Alzheimer's, TBI (traumatic brain injury) and CTE (chronic traumatic encephalopathy).
3. Our patented technologies may form a safe basis of brain-machine interface. It can assist AI (Artificial Intelligence) based on our brain memory circuits theory: "Free Energy, Functional Group Interaction and Memory Protein Stability Equilibrium", which was first presented on 2013 AAIC (Alzheimer's Association International Conference) in Boston. ACL is patiently waiting for Elon Musk's call.
Interested institutions for partnership and/or investment
Please contact:
Mr. Wayne Shentu
55 New Street, Ste. 14
Ephrata, PA 17522, U.S.
Tel: (717) 814-5752
communication@ablecerebral.com
In memory of Professor J. Howard Rytting, a diabetic and devoted his knowledge of thermodynamics to bio-pharmaceutical research
